Literature DB >> 24037254

Dual antiplatelet therapy dilemmas: duration and choice of antiplatelets in acute coronary syndromes.

Matthew Tomey1, Roxana Mehran.   

Abstract

Dual antiplatelet therapy (DAPT) is a key component of therapy for acute coronary syndromes managed with and without percutaneous coronary intervention. Recent advances have given patients a wider variety of therapeutic options including the use of combinations of agents, dosing strategies, and durations of therapy. The optimal regimen minimizes thrombotic risk without increasing the risk of bleeding. Choosing the best therapy for each patient is an individualized dilemma that requires new, evidence-based tools to support regimen decision-making.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24037254     DOI: 10.1007/s11886-013-0405-z

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  48 in total

1.  Pharmacogenomics and clopidogrel: irrational exuberance?

Authors:  Steven E Nissen
Journal:  JAMA       Date:  2011-12-28       Impact factor: 56.272

2.  Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry.

Authors:  Bo Lagerqvist; Jörg Carlsson; Ole Fröbert; Johan Lindbäck; Fredrik Scherstén; Ulf Stenestrand; Stefan K James
Journal:  Circ Cardiovasc Interv       Date:  2009-09-08       Impact factor: 6.546

3.  2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Alice K Jacobs
Journal:  Circulation       Date:  2011-03-28       Impact factor: 29.690

4.  Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.

Authors:  A Lala; J S Berger; G Sharma; J S Hochman; R Scott Braithwaite; J A Ladapo
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

5.  Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.

Authors:  Elisabet Nikolic; Magnus Janzon; Ole Hauch; Lars Wallentin; Martin Henriksson
Journal:  Eur Heart J       Date:  2012-06-19       Impact factor: 29.983

6.  Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Authors:  Dimitrios Alexopoulos; Anastasia Galati; Ioanna Xanthopoulou; Eleni Mavronasiou; George Kassimis; Konstantinos C Theodoropoulos; George Makris; Anastasia Damelou; Grigorios Tsigkas; George Hahalis; Periklis Davlouros
Journal:  J Am Coll Cardiol       Date:  2012-07-17       Impact factor: 24.094

7.  A risk score to predict bleeding in patients with acute coronary syndromes.

Authors:  Roxana Mehran; Stuart J Pocock; Eugenia Nikolsky; Tim Clayton; George D Dangas; Ajay J Kirtane; Helen Parise; Martin Fahy; Steven V Manoukian; Frederick Feit; Magnus E Ohman; Bernard Witzenbichler; Giulio Guagliumi; Alexandra J Lansky; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2010-06-08       Impact factor: 24.094

8.  Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.

Authors:  Hyeon-Cheol Gwon; Joo-Yong Hahn; Kyung Woo Park; Young Bin Song; In-Ho Chae; Do-Sun Lim; Kyoo-Rok Han; Jin-Ho Choi; Seung-Hyuk Choi; Hyun-Jae Kang; Bon-Kwon Koo; Taehoon Ahn; Jung-Han Yoon; Myung-Ho Jeong; Taek-Jong Hong; Woo-Young Chung; Young-Jin Choi; Seung-Ho Hur; Hyuck-Moon Kwon; Dong-Woon Jeon; Byung-Ok Kim; Si-Hoon Park; Nam-Ho Lee; Hui-Kyung Jeon; Yangsoo Jang; Hyo-Soo Kim
Journal:  Circulation       Date:  2011-12-16       Impact factor: 29.690

9.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Authors:  M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245

10.  Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.

Authors:  John M Lasala; David A Cox; David Dobies; Kenneth Baran; William B Bachinsky; Edwin W Rogers; Jeffrey A Breall; David H Lewis; Aijun Song; Ruth M Starzyk; Stephen R Mascioli; Keith D Dawkins; Donald S Baim
Journal:  Circ Cardiovasc Interv       Date:  2009-07-22       Impact factor: 6.546

View more
  1 in total

Review 1.  Interventional Options for Coronary Artery Calcification.

Authors:  Matthew I Tomey; Samin K Sharma
Journal:  Curr Cardiol Rep       Date:  2016-02       Impact factor: 2.931

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.